This reference hub prioritizes regulatory agencies, official prescribing information and peer-reviewed clinical evidence.
Regulatory Sources
U.S. Food and Drug Administration — KISQALI
The FDA prescribing information provides current U.S. indications, dosing, warnings, interactions, pharmacology and clinical information.
DailyMed — KISQALI
DailyMed provides the current U.S. labeling record, including the July 2026 revision.
European Medicines Agency — Kisqali EPAR
The EMA provides European authorization, indication and product information for Kisqali.
Clinical literature
The MONALEESA program provides major clinical evidence for ribociclib in HR-positive/HER2-negative advanced or metastatic breast cancer.
Manufacturer/development information
Novartis states that Kisqali was developed by the Novartis Institutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals.
Ribokis-specific documentation
The manufacturer, authorization status, manufacturing site and regulatory documentation for Ribokis are Everest Pharmaceuticals Ltd.